Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
4 pending office actions • 3 art units • 4 examiners • 0 of 4 (0%) have an AI response strategy ready
Entera Bio Ltd. is managing 4 pending office actions within the Biotechnology & Pharmaceuticals technology area. These matters are distributed across 3 distinct art units, indicating a focused but slightly varied technical classification for their pharmaceutical applications. The company is working with 4 distinct examiners, which means that every pending action is assigned to a different individual.
ALLEY, GENEVIEVE S is the busiest examiner for Entera Bio Ltd., currently overseeing 1 pending office action. Because each of the 4 pending office actions is with a different examiner, the company must navigate 4 separate sets of examiner preferences and backgrounds. This distribution across 3 art units suggests that practitioners need to be prepared for the specific evidentiary requirements common in biotechnology and pharmaceutical examinations across multiple specialized groups.
The presence of 4 distinct examiners for only 4 pending office actions means there is no concentration of workload that would allow for a unified prosecution strategy with a single individual. For a practitioner, this requires a high degree of adaptability, as the arguments successful with ALLEY, GENEVIEVE S may not resonate with the other 3 examiners. The focus on the Biotechnology & Pharmaceuticals area remains consistent, but the personnel diversity at the patent office requires a case-by-case approach.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 2 (50%) |
| Double-patenting + other | 2 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| ALLEY, GENEVIEVE S | 1 | 60.3% | +48.2% |
| KONOPELSKI SNAVEL, SARA ELIZABETH | 1 | 33.3% | +38.9% |
| PALENIK, JEFFREY T | 1 | 53.6% | +27.2% |
| REYNOLDS, FRED H | 1 | 33.0% | +39.2% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18432185 | TREATMENT OF HYPOPARATHYROIDISM | REYNOLDS, FRED H | 30d overdue |
| 19544782 | FORMULATIONS COMPRISING A COMBINATION OF ACID-NEUTRALIZING POLYMERIC AND NON-POLYMERIC SUBSTANCES FOR ORAL ADMINISTRATION OF ACTIVE AGENTS | ALLEY, GENEVIEVE S | — |
| 19440230 | FORMULATIONS COMPRISING ACID-NEUTRALIZING POLYMER FOR ORAL ADMINISTRATION OF PARATHYROID HORMONE | KONOPELSKI SNAVEL, SARA ELIZABETH | — |
| 18798864 | FORMULATIONS FOR ORAL ADMINISTRATION OF ACTIVE AGENTS | PALENIK, JEFFREY T | — |
| Art Unit | Apps |
|---|---|
| 1658 | 2 |
| 1617 | 1 |
| 1615 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19544782 | FORMULATIONS COMPRISING A COMBINATION OF ACID-NEUTRALIZING POLYMERIC AND NON-POLYMERIC SUBSTANCES FOR ORAL ADMINISTRATION OF ACTIVE AGENTS | ALLEY, GENEVIEVE S | 1617 | §103§112DP | Non-Final OA | — | Pending | Feb 19, 2026 |
| 19440230 | FORMULATIONS COMPRISING ACID-NEUTRALIZING POLYMER FOR ORAL ADMINISTRATION OF PARATHYROID HORMONE | KONOPELSKI SNAVEL, SARA ELIZABETH | 1658 | §103DP | Non-Final OA | — | Pending | Jan 05, 2026 |
| 18798864 | FORMULATIONS FOR ORAL ADMINISTRATION OF ACTIVE AGENTS | PALENIK, JEFFREY T | 1615 | §103 | Final Rejection | — | Pending | Aug 09, 2024 |
| 18432185 | TREATMENT OF HYPOPARATHYROIDISM | REYNOLDS, FRED H | 1658 | §103Other | Final Rejection | 30d overdue | Pending | Feb 05, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial